{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:56:16Z","timestamp":1788692176489,"version":"build-2803163510"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2017,10,2]],"date-time":"2017-10-02T00:00:00Z","timestamp":1506902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1038\/onc.2017.346","type":"journal-article","created":{"date-parts":[[2017,10,2]],"date-time":"2017-10-02T14:59:02Z","timestamp":1506956342000},"page":"439-449","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy"],"prefix":"10.1038","volume":"37","author":[{"given":"V","family":"Mett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E A","family":"Komarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Bespalov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Brackett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A S","family":"Gleiberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I A","family":"Toshkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Ayg\u00fcn-Sunar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Karasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bapardekar-Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O V","family":"Kurnasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A L","family":"Osterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P S","family":"Stanhope-Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M T","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B A","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A V","family":"Gudkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,2]]},"reference":[{"key":"BFonc2017346_CR1","doi-asserted-by":"publisher","first-page":"7009","DOI":"10.4049\/jimmunol.167.12.7009","volume":"167","author":"TD Eaves-Pyles","year":"2001","unstructured":"Eaves-Pyles TD, Wong HR, Odoms K, Pyles RB . Salmonella flagellin-dependent proinflammatory responses are localized to the conserved amino and carboxyl regions of the protein. J Immunol 2001; 167: 7009\u20137016.","journal-title":"J Immunol"},{"key":"BFonc2017346_CR2","doi-asserted-by":"publisher","first-page":"120ra116","DOI":"10.1126\/scitranslmed.3002868","volume":"4","author":"J Garaude","year":"2012","unstructured":"Garaude J, Kent A, van Rooijen N, Blander JM . Simultaneous targeting of toll- and nod-like receptors induces effective tumor-specific immune responses. Sci Transl Med 2012; 4: 120ra116.","journal-title":"Sci Transl Med"},{"key":"BFonc2017346_CR3","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1053\/j.gastro.2008.04.022","volume":"135","author":"SH Rhee","year":"2008","unstructured":"Rhee SH, Im E, Pothoulakis C . Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 2008; 135: 518\u2013528.","journal-title":"Gastroenterology"},{"key":"BFonc2017346_CR4","doi-asserted-by":"publisher","first-page":"6624","DOI":"10.4049\/jimmunol.176.11.6624","volume":"176","author":"L Sfondrini","year":"2006","unstructured":"Sfondrini L, Rossini A, Besusso D, Merlo A, Tagliabue E, Menard S et al. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol 2006; 176: 6624\u20136630.","journal-title":"J Immunol"},{"key":"BFonc2017346_CR5","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0022-3468(03)00196-9","volume":"38","author":"LJ Soto 3rd","year":"2003","unstructured":"Soto LJ 3rd, Sorenson BS, Kim AS, Feltis BA, Leonard AS, Saltzman DA . Attenuated Salmonella typhimurium prevents the establishment of unresectable hepatic metastases and improves survival in a murine model. J Pediatr Surg 2003; 38: 1075\u20131079.","journal-title":"J Pediatr Surg"},{"key":"BFonc2017346_CR6","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1158\/0008-5472.CAN-10-1993","volume":"71","author":"Z Cai","year":"2011","unstructured":"Cai Z, Sanchez A, Shi Z, Zhang T, Liu M, Zhang D . Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res 2011; 71: 2466\u20132475.","journal-title":"Cancer Res"},{"key":"BFonc2017346_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ijrobp.2011.05.055","volume":"83","author":"LG Burdelya","year":"2012","unstructured":"Burdelya LG, Gleiberman AS, Toshkov I, Aygun-Sunar S, Bapardekar M, Manderscheid-Kern P et al. Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy. Int J Radiat Oncol Biol Phys 2012; 83: 228\u2013234.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFonc2017346_CR8","doi-asserted-by":"publisher","first-page":"E1857","DOI":"10.1073\/pnas.1222805110","volume":"110","author":"LG Burdelya","year":"2013","unstructured":"Burdelya LG, Brackett CM, Kojouharov B, Gitlin II, Leonova KI, Gleiberman AS et al. Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonist. Proc Natl Acad Sci USA 2013; 110: E1857\u2013E1866.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2017346_CR9","doi-asserted-by":"publisher","first-page":"E874","DOI":"10.1073\/pnas.1521359113","volume":"113","author":"CM Brackett","year":"2016","unstructured":"Brackett CM, Kojouharov B, Veith J, Greene KF, Burdelya LG, Gollnick SO et al. Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis. Proc Natl Acad Sci USA 2016; 113: E874\u2013E883.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2017346_CR10","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.18632\/oncotarget.6500","volume":"7","author":"H Yang","year":"2016","unstructured":"Yang H, Brackett CM, Morales-Tirado VM, Li Z, Zhang Q, Wilson MW et al. The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism. Oncotarget 2016; 7: 2936\u20132950.","journal-title":"Oncotarget"},{"key":"BFonc2017346_CR11","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.jss.2009.02.023","volume":"164","author":"C Yam","year":"2010","unstructured":"Yam C, Zhao M, Hayashi K, Ma H, Kishimoto H, McElroy M et al. Monotherapy with a tumor-targeting mutant of S. typhimurium inhibits liver metastasis in a mouse model of pancreatic cancer. J Surg Res 2010; 164: 248\u2013255.","journal-title":"J Surg Res"},{"key":"BFonc2017346_CR12","doi-asserted-by":"publisher","first-page":"5677","DOI":"10.4049\/jimmunol.1002156","volume":"185","author":"SB Mizel","year":"2010","unstructured":"Mizel SB, Bates JT . Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 2010; 185: 5677\u20135682.","journal-title":"J Immunol"},{"key":"BFonc2017346_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.5056\/jnm.2011.17.1.28","volume":"17","author":"SH Rhee","year":"2011","unstructured":"Rhee SH . Basic and translational understandings of microbial recognition by toll-like receptors in the intestine. J Neurogastroenterol Motil 2011; 17: 28\u201334.","journal-title":"J Neurogastroenterol Motil"},{"key":"BFonc2017346_CR14","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1128\/IAI.72.5.2810-2816.2004","volume":"72","author":"C Cuadros","year":"2004","unstructured":"Cuadros C, Lopez-Hernandez FJ, Dominguez AL, McClelland M, Lustgarten J . Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 2004; 72: 2810\u20132816.","journal-title":"Infect Immun"},{"key":"BFonc2017346_CR15","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.4049\/jimmunol.170.10.5165","volume":"170","author":"TK Means","year":"2003","unstructured":"Means TK, Hayashi F, Smith KD, Aderem A, Luster AD . The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol 2003; 170: 5165\u20135175.","journal-title":"J Immunol"},{"key":"BFonc2017346_CR16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1189\/jlb.1012501","volume":"93","author":"S Kaczanowska","year":"2013","unstructured":"Kaczanowska S, Joseph AM, Davila E . TLR agonists: our best frenemy in cancer immunotherapy. J Leukocyte Biol 2013; 93: 847\u2013863.","journal-title":"J Leukocyte Biol"},{"key":"BFonc2017346_CR17","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.crvi.2004.04.002","volume":"327","author":"S Akira","year":"2004","unstructured":"Akira S, Takeda K . Functions of toll-like receptors: lessons from KO mice. C R Biol 2004; 327: 581\u2013589.","journal-title":"C R Biol"},{"key":"BFonc2017346_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/mi.2010.57","volume":"4","author":"FA Carvalho","year":"2011","unstructured":"Carvalho FA, Aitken JD, Gewirtz AT, Vijay-Kumar M . TLR5 activation induces secretory interleukin-1 receptor antagonist (sIL-1Ra) and reduces inflammasome-associated tissue damage. Mucosal Immunol 2011; 4: 102\u2013111.","journal-title":"Mucosal Immunol"},{"key":"BFonc2017346_CR19","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1002\/eji.201040421","volume":"40","author":"M Vijay-Kumar","year":"2010","unstructured":"Vijay-Kumar M, Carvalho FA, Aitken JD, Fifadara NH, Gewirtz AT . TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin. Eur J Immunol 2010; 40: 3528\u20133534.","journal-title":"Eur J Immunol"},{"key":"BFonc2017346_CR20","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1089\/hum.1998.9.16-2363","volume":"9","author":"S Hemmi","year":"1998","unstructured":"Hemmi S, Geertsen R, Mezzacasa A, Peter I, Dummer R . The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. Hum Gene Ther 1998; 9: 2363\u20132373.","journal-title":"Hum Gene Ther"},{"key":"BFonc2017346_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s12094-014-1259-6","volume":"17","author":"EM Fernandez-Garcia","year":"2015","unstructured":"Fernandez-Garcia EM, Vera-Badillo FE, Perez-Valderrama B, Matos-Pita AS, Duran I . Immunotherapy in prostate cancer: review of the current evidence. Clin Transl Oncol 2015; 17: 339\u2013357.","journal-title":"Clin Transl Oncol"},{"key":"BFonc2017346_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/sj.cr.7310017","volume":"16","author":"Y Shi","year":"2006","unstructured":"Shi Y, Liu CH, Roberts AI, Das J, Xu G, Ren G et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know. Cell Res 2006; 16: 126\u2013133.","journal-title":"Cell Res"},{"key":"BFonc2017346_CR23","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","volume":"90","author":"G Dranoff","year":"1993","unstructured":"Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539\u20133543.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2017346_CR24","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.urolonc.2005.08.021","volume":"24","author":"JW Simons","year":"2006","unstructured":"Simons JW, Sacks N . Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol 2006; 24: 419\u2013424.","journal-title":"Urol Oncol"},{"key":"BFonc2017346_CR25","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.1158\/1078-0432.CCR-04-2337","volume":"11","author":"A Michael","year":"2005","unstructured":"Michael A, Ball G, Quatan N, Wushishi F, Russell N, Whelan J et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005; 11: 4469\u20134478.","journal-title":"Clin Cancer Res"},{"key":"BFonc2017346_CR26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0065-2776(06)90008-X","volume":"90","author":"AJ Korman","year":"2006","unstructured":"Korman AJ, Peggs KS, Allison JP . Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006; 90: 297\u2013339.","journal-title":"Adv Immunol"},{"key":"BFonc2017346_CR27","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.juro.2007.05.117","volume":"178","author":"PM Arlen","year":"2007","unstructured":"Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007; 178: 1515\u20131520.","journal-title":"J Urol"},{"key":"BFonc2017346_CR28","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1158\/1078-0432.CCR-09-1910","volume":"15","author":"DM Lubaroff","year":"2009","unstructured":"Lubaroff DM, Konety BR, Link B, Gerstbrein J, Madsen T, Shannon M et al. Phase I clinical trial of an adenovirus\/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res 2009; 15: 7375\u20137380.","journal-title":"Clin Cancer Res"},{"key":"BFonc2017346_CR29","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","volume":"15","author":"ED Kwon","year":"2014","unstructured":"Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 700\u2013712.","journal-title":"Lancet Oncol"},{"key":"BFonc2017346_CR30","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443\u20132454.","journal-title":"N Engl J Med"},{"key":"BFonc2017346_CR31","doi-asserted-by":"publisher","first-page":"5283","DOI":"10.1158\/1078-0432.CCR-13-2151","volume":"19","author":"RJ Sullivan","year":"2013","unstructured":"Sullivan RJ, Lorusso PM, Flaherty KT . The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be. Clin Cancer Res 2013; 19: 5283\u20135291.","journal-title":"Clin Cancer Res"},{"key":"BFonc2017346_CR32","doi-asserted-by":"publisher","first-page":"5300","DOI":"10.1158\/1078-0432.CCR-13-0143","volume":"19","author":"PA Ott","year":"2013","unstructured":"Ott PA, Hodi FS, Robert C . CTLA-4 and PD-1\/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 2013; 19: 5300\u20135309.","journal-title":"Clin Cancer Res"},{"key":"BFonc2017346_CR33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00403-014-1457-7","volume":"306","author":"A Mamalis","year":"2014","unstructured":"Mamalis A, Garcha M, Jagdeo J . Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res 2014; 306: 511\u2013519.","journal-title":"Arch Dermatol Res"},{"key":"BFonc2017346_CR34","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1634\/theoncologist.2013-0171","volume":"18","author":"PM Forde","year":"2013","unstructured":"Forde PM, Reiss KA, Zeidan AM, Brahmer JR . What lies within: novel strategies in immunotherapy for non-small cell lung cancer. Oncologist 2013; 18: 1203\u20131213.","journal-title":"Oncologist"},{"key":"BFonc2017346_CR35","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252\u2013264.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2017346_CR36","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455\u20132465.","journal-title":"N Engl J Med"},{"key":"BFonc2017346_CR37","first-page":"3325","volume":"57","author":"BA Foster","year":"1997","unstructured":"Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM . Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997; 57: 3325\u20133330.","journal-title":"Cancer Res"},{"key":"BFonc2017346_CR38","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1073\/pnas.92.8.3439","volume":"92","author":"NM Greenberg","year":"1995","unstructured":"Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 3439\u20133443.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2017346_CR39","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1177\/019262339602400414","volume":"24","author":"JR Gingrich","year":"1996","unstructured":"Gingrich JR, Greenberg NM . A transgenic mouse prostate cancer model. Toxicol Pathol 1996; 24: 502\u2013504.","journal-title":"Toxicol Pathol"},{"key":"BFonc2017346_CR40","first-page":"5125","volume":"60","author":"S Gupta","year":"2000","unstructured":"Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, Mukhtar H . Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Res 2000; 60: 5125\u20135133.","journal-title":"Cancer Res"},{"key":"BFonc2017346_CR41","first-page":"2444","volume":"60","author":"AA Hurwitz","year":"2000","unstructured":"Hurwitz AA, Foster BA, Kwon ED, Truong T, Choi EM, Greenberg NM et al. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res 2000; 60: 2444\u20132448.","journal-title":"Cancer Res"},{"key":"BFonc2017346_CR42","first-page":"6777","volume":"61","author":"R Mentor-Marcel","year":"2001","unstructured":"Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A . Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res 2001; 61: 6777\u20136782.","journal-title":"Cancer Res"},{"key":"BFonc2017346_CR43","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/pros.10215","volume":"55","author":"PJ Kaplan-Lefko","year":"2003","unstructured":"Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003; 55: 219\u2013237.","journal-title":"Prostate"},{"key":"BFonc2017346_CR44","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1126\/science.1154986","volume":"320","author":"LG Burdelya","year":"2008","unstructured":"Burdelya LG, Krivokrysenko VI, Tallant TC, Strom E, Gleiberman AS, Gupta D et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 2008; 320: 226\u2013230.","journal-title":"Science"},{"key":"BFonc2017346_CR45","doi-asserted-by":"publisher","first-page":"e1151593","DOI":"10.1080\/2162402X.2016.1151593","volume":"5","author":"GM Rodriguez","year":"2016","unstructured":"Rodriguez GM, Bobbala D, Serrano D, Mayhue M, Champagne A, Saucier C et al. NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8(+) T lymphocytes. Oncoimmunology 2016; 5: e1151593.","journal-title":"Oncoimmunology"},{"key":"BFonc2017346_CR46","doi-asserted-by":"publisher","first-page":"15074","DOI":"10.1073\/pnas.96.26.15074","volume":"96","author":"ED Kwon","year":"1999","unstructured":"Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA 1999; 96: 15074\u201315079.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2017346_CR47","first-page":"3812","volume":"62","author":"KA Rauen","year":"2002","unstructured":"Rauen KA, Sudilovsky D, Le JL, Chew KL, Hann B, Weinberg V et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. Cancer Res 2002; 62: 3812\u20133818.","journal-title":"Cancer Res"},{"key":"BFonc2017346_CR48","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1038\/sj.cgt.7700174","volume":"7","author":"FC Marini 3rd","year":"2000","unstructured":"Marini FC 3rd, Yu Q, Wickham T, Kovesdi I, Andreeff M . Adenovirus as a gene therapy vector for hematopoietic cells. Cancer Gene Ther 2000; 7: 816\u2013825.","journal-title":"Cancer Gene Ther"},{"key":"BFonc2017346_CR49","doi-asserted-by":"publisher","first-page":"6555","DOI":"10.2174\/1381612820666140826153347","volume":"20","author":"TM Glavan","year":"2014","unstructured":"Glavan TM, Pavelic J . The exploitation of Toll-like receptor 3 signaling in cancer therapy. Curr Pharma Design 2014; 20: 6555\u20136564.","journal-title":"Curr Pharma Design"},{"key":"BFonc2017346_CR50","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1517\/13543784.17.7.1051","volume":"17","author":"T Meyer","year":"2008","unstructured":"Meyer T, Stockfleth E . Clinical investigations of Toll-like receptor agonists. Exp Opin Investig Drugs 2008; 17: 1051\u20131065.","journal-title":"Exp Opin Investig Drugs"},{"key":"BFonc2017346_CR51","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.4049\/jimmunol.0902401","volume":"184","author":"R Galli","year":"2010","unstructured":"Galli R, Starace D, Busa R, Angelini DF, Paone A, De Cesaris P et al. TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types. J Immunol 2010; 184: 6658\u20136669.","journal-title":"J Immunol"},{"key":"BFonc2017346_CR52","doi-asserted-by":"publisher","first-page":"e85587","DOI":"10.1371\/journal.pone.0085587","volume":"9","author":"ND Leigh","year":"2014","unstructured":"Leigh ND, Bian G, Ding X, Liu H, Aygun-Sunar S, Burdelya LG et al. A flagellin-derived toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity. PLoS ONE 2014; 9: e85587.","journal-title":"PLoS ONE"},{"key":"BFonc2017346_CR53","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/icb.2014.74","volume":"93","author":"FM de Melo","year":"2015","unstructured":"de Melo FM, Braga CJ, Pereira FV, Maricato JT, Origassa CS, Souza MF et al. Anti-metastatic immunotherapy based on mucosal administration of flagellin and immunomodulatory P10. Immunol Cell Biol 2015; 93: 86\u201398.","journal-title":"Immunol Cell Biol"},{"key":"BFonc2017346_CR54","doi-asserted-by":"publisher","first-page":"e1081328","DOI":"10.1080\/2162402X.2015.1081328","volume":"5","author":"SE Lee","year":"2016","unstructured":"Lee SE, Hong SH, Verma V, Lee YS, Duong TN, Jeong K et al. Flagellin is a strong vaginal adjuvant of a therapeutic vaccine for genital cancer. Oncoimmunology 2016; 5: e1081328.","journal-title":"Oncoimmunology"},{"key":"BFonc2017346_CR55","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/cgt.2008.85","volume":"16","author":"C Tosch","year":"2009","unstructured":"Tosch C, Geist M, Ledoux C, Ziller-Remi C, Paul S, Erbs P et al. Adenovirus-mediated gene transfer of pathogen-associated molecular patterns for cancer immunotherapy. Cancer Gene Ther 2009; 16: 310\u2013319.","journal-title":"Cancer Gene Ther"},{"key":"BFonc2017346_CR56","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1158\/0008-5472.CAN-12-1740","volume":"73","author":"X Yu","year":"2013","unstructured":"Yu X, Guo C, Yi H, Qian J, Fisher PB, Subjeck JR et al. A multifunctional chimeric chaperone serves as a novel immune modulator inducing therapeutic antitumor immunity. Cancer Res 2013; 73: 2093\u20132103.","journal-title":"Cancer Res"},{"key":"BFonc2017346_CR57","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.4049\/jimmunol.1000027","volume":"185","author":"A Faham","year":"2010","unstructured":"Faham A, Altin JG . Antigen-containing liposomes engrafted with flagellin-related peptides are effective vaccines that can induce potent antitumor immunity and immunotherapeutic effect. J Immunol 2010; 185: 1744\u20131754.","journal-title":"J Immunol"},{"key":"BFonc2017346_CR58","doi-asserted-by":"publisher","first-page":"e1076609","DOI":"10.1080\/2162402X.2015.1076609","volume":"5","author":"S Kaczanowska","year":"2016","unstructured":"Kaczanowska S, Davila E . Ameliorating the tumor microenvironment for antitumor responses through TLR5 ligand-secreting T cells. Oncoimmunology 2016; 5: e1076609.","journal-title":"Oncoimmunology"},{"key":"BFonc2017346_CR59","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1001294","volume":"363","author":"PW Kantoff","year":"2010","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411\u2013422.","journal-title":"N Engl J Med"},{"key":"BFonc2017346_CR60","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1126\/science.1215584","volume":"335","author":"SI Yoon","year":"2012","unstructured":"Yoon SI, Kurnasov O, Natarajan V, Hong M, Gudkov AV, Osterman AL et al. Structural basis of TLR5-flagellin recognition and signaling. Science 2012; 335: 859\u2013864.","journal-title":"Science"},{"key":"BFonc2017346_CR61","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1634\/stemcells.2006-0009","volume":"24","author":"C Fougere-Deschatrette","year":"2006","unstructured":"Fougere-Deschatrette C, Imaizumi-Scherrer T, Strick-Marchand H, Morosan S, Charneau P, Kremsdorf D et al. Plasticity of hepatic cell differentiation: bipotential adult mouse liver clonal cell lines competent to differentiate in vitro and in vivo. Stem Cells 2006; 24: 2098\u20132109.","journal-title":"Stem Cells"},{"key":"BFonc2017346_CR62","doi-asserted-by":"publisher","first-page":"e0135388","DOI":"10.1371\/journal.pone.0135388","volume":"10","author":"VI Krivokrysenko","year":"2015","unstructured":"Krivokrysenko VI, Toshkov IA, Gleiberman AS, Krasnov P, Shyshynova I, Bespalov I et al. The Toll-like receptor 5 agonist entolimod mitigates lethal acute radiation syndrome in non-human primates. PLoS ONE 2015; 10: e0135388.","journal-title":"PLoS ONE"},{"key":"BFonc2017346_CR63","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10719-014-9548-4","volume":"31","author":"SA Patil","year":"2014","unstructured":"Patil SA, Bshara W, Morrison C, Chandrasekaran EV, Matta KL, Neelamegham S . Overexpression of alpha2,3sialyl T-antigen in breast cancer determined by miniaturized glycosyltransferase assays and confirmed using tissue microarray immunohistochemical analysis. Glycoconjugate J 2014; 31: 509\u2013521.","journal-title":"Glycoconjugate J"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/onc2017346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/onc2017346","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/onc.2017.346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/onc2017346.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T05:02:14Z","timestamp":1684472534000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2017346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,2]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["BFonc2017346"],"URL":"https:\/\/doi.org\/10.1038\/onc.2017.346","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,2]]},"assertion":[{"value":"26 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}